- Home
- AGEN vs BAER Comparison
AGEN vs BAER Comparison
Compare AGEN & BAER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- BAER
- Stock Information
- Founded
- AGEN 1994
- BAER 2014
- Country
- AGEN United States
- BAER United States
- Employees
- AGEN N/A
- BAER N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- BAER Blank Checks
- Sector
- AGEN Health Care
- BAER Finance
- Exchange
- AGEN Nasdaq
- BAER Nasdaq
- Market Cap
- AGEN 87.7M
- BAER 77.2M
- IPO Year
- AGEN 2000
- BAER N/A
- Fundamental
- Price
- AGEN $5.16
- BAER $1.89
- Analyst Decision
- AGEN Buy
- BAER Strong Buy
- Analyst Count
- AGEN 4
- BAER 1
- Target Price
- AGEN $13.00
- BAER $5.25
- AVG Volume (30 Days)
- AGEN 1.6M
- BAER 248.3K
- Earning Date
- AGEN 08-07-2025
- BAER 08-11-2025
- Dividend Yield
- AGEN N/A
- BAER N/A
- EPS Growth
- AGEN N/A
- BAER N/A
- EPS
- AGEN N/A
- BAER N/A
- Revenue
- AGEN $99,524,000.00
- BAER $108,752,000.00
- Revenue This Year
- AGEN $14.49
- BAER $13.26
- Revenue Next Year
- AGEN N/A
- BAER N/A
- P/E Ratio
- AGEN N/A
- BAER N/A
- Revenue Growth
- AGEN N/A
- BAER 51.36
- 52 Week Low
- AGEN $1.38
- BAER $1.02
- 52 Week High
- AGEN $18.74
- BAER $4.44
- Technical
- Relative Strength Index (RSI)
- AGEN 62.39
- BAER 67.19
- Support Level
- AGEN $5.06
- BAER $1.79
- Resistance Level
- AGEN $6.35
- BAER $1.94
- Average True Range (ATR)
- AGEN 0.59
- BAER 0.14
- MACD
- AGEN 0.12
- BAER 0.03
- Stochastic Oscillator
- AGEN 65.00
- BAER 93.05
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About BAER Bridger Aerospace Group Holdings Inc.
Bridger Aerospace Group Holdings Inc operates as an aerial firefighting company. It provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services using next-generation technology and environmentally friendly and sustainable firefighting methods. Bridger Aerospace provides aerial firefighting and wildfire management services to federal and state government agencies, including the United States Forest Service, across the nation. The company's portfolio is organized across two offerings: Fire Suppression, which Consists of deploying specialized Viking CL-415EAF (Super Scooper) aircraft to drop large amounts of water quickly and directly on wildfires, and Aerial Surveillance, providing aerial surveillance via manned aircraft for fire suppression aircraft.